Back to Company Profile

Alpha Profiles · Company Profile

ABBOTT LABORATORIES

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions.

https://registry.alpha.ac/companies/abbott-laboratories

Entity: Public listing published
Primary listing: NYSE: ABT
Verification: Partially verified
Last reviewed: 2026-10-15T04:45:03.089715+00:00

Overview

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: ABT executive roster sourceMay 3, 2026

John A. McCoy, Jr.

Vice President, Finance and Controller

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: ABT executive roster sourceMay 3, 2026

Philip P. Boudreau

Executive Vice President, Finance and Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: ABT executive roster sourceMay 3, 2026

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: ABT executive roster sourceMay 3, 2026

Chairman of the Board and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: ABT executive roster sourceMay 3, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 15, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

14 public records

Claire Babineaux-Fontenot

Director

Independence not statedAuditPublic PolicyESG

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Daniel J. Starks

Director

Independence not statedCompensation · ChairPublic PolicyExecutiveESG

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Darren W. McDew

Director

Independence not statedNominations and GovernancePublic PolicyESG

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

John G. Stratton

Director

Independence not statedAuditNominations and Governance · ChairExecutive

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Michael F. Roman

Director

Independence not statedCompensationPublic PolicyExecutiveESG · Chair

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Michael G. O'Grady

Director

Independence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Michelle A. Kumbier

Director

Independence not statedAuditCompensation

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Nancy McKinstry

Director

Independence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Director

Independence not stated

State: confirmed
Effective: From Mar 13, 2026
Confidence: 92%
Evidence: ABT DEF 14A director slateMar 13, 2026

Director

Independence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Director

Independence not statedAuditNominations and Governance

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Director

Independence not statedExecutive

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Sally E. Blount

Director

Independence not stated

State: confirmed
Effective: From Mar 13, 2026
Confidence: 92%
Evidence: ABT DEF 14A director slateMar 13, 2026

Sally E. Blount Ph.D

Director

Independence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: Abbott Laboratories director board sourceMar 13, 2026

Committees

6 public records

Membership and chair roles are projected from current board seats. A chair is shown only when a stored chair flag says so.

Audit

Chair: Nancy McKinstry
Members: Nancy McKinstry (Chair); Claire Babineaux-Fontenot; John G. Stratton; Michelle A. Kumbier; Paola Gonzalez

Compensation

Chair: Daniel J. Starks
Members: Daniel J. Starks (Chair); Michael F. Roman; Michelle A. Kumbier; Nancy McKinstry

ESG

Chair: Michael F. Roman
Members: Michael F. Roman (Chair); Claire Babineaux-Fontenot; Daniel J. Starks; Darren W. McDew

Executive

Chair: Not stated
Members: Daniel J. Starks; John G. Stratton; Michael F. Roman; Nancy McKinstry; Robert B. Ford

Nominations and Governance

Chair: John G. Stratton
Members: John G. Stratton (Chair); Darren W. McDew; Paola Gonzalez

Public Policy

Chair: Not stated
Members: Claire Babineaux-Fontenot; Daniel J. Starks; Darren W. McDew; Michael F. Roman

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-15T04:45:03.089715+00:00